EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieQuerschnittstudieOpen Access · CC BY-NC 4.0

Patient-reported adverse events and management of antifibrotic therapy in IPF: A multicenter, cross-sectional real-world study

Onur Turan iD, Erhan Uğurlu, Özge Oral Tapan, Nurhan Sarıoğlu, Gülru Polat, Şule Çilekar, Özgür Batum, Şule Taş Gülen

Therapeutic Advances in Respiratory Disease · 2026-08 · 20

DOI: 10.1177/17534666261475558 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 31.08.2026. Verfasst von Onur Turan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chest Diseases Department, Izmir Katip Celebi University, İzmir, Turkey. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Pyridones, Indoles, Antifibrotic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antifibrotic agents slow disease progression and improve survival in IPF, yet real-life data on their use in Turkey are limited.

Objectives

This study aimed to compare the side effects of antifibrotics in IPF patients.

Design

A cross-sectional survey was conducted in 8 centers across 6 provinces in the Aegean Region.

Methods

There were 470 IPF patients who completed a 30-item face-to-face questionnaire. Adverse events and their management were compared between pirfenidone and nintedanib users.

Results

Among 470 patients, 50.6% used pirfenidone and 49.4% nintedanib. Overall, 70.6% reported at least one side effect (75.5% nintedanib vs. 66% pirfenidone, p=0.023). Medical treatment was required in 30.9% and dose reduction in 18.9%. The most common side effects were diarrhea (30.6%), appetite loss (24.9%), and nausea (22.3%). Diarrhea (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisPyridonesIndolesAntifibrotic AgentsHumansCross-Sectional StudiesFemaleMaleAgedMiddle AgedTurkeySurveys and QuestionnairesTreatment Outcome

Stichwörter der Autor:innen

IPFadverse eventsantifibrotic therapynintedanibpirfenidoneside effects

Substanzen

pirfenidonenintedanibPyridonesIndolesAntifibrotic Agents

Autor:innen und Institutionen

  • Chest Diseases Department, Izmir Katip Celebi University, İzmir, Turkey.
  • Pulmonology Department, Pamukkale University, Denizli, Turkey.
  • Pulmonology Department, Muğla Sıtkı Koçman University, Muğla, Turkey.
  • Pulmonology Department, Balıkesir University, Balıkesir, Turkey.
  • Pulmonology Department, University of Health Sciences, Suat Seren Training and Research Hospital, İzmir, Turkey.
  • Pulmonology Department, AFSU Health and Application Center, Afyon, Turkey.

ORCID-Profile: Onur Turan

Zitieren

APA

Turan, O., Uğurlu, E., Oral Tapan, Ö., Sarıoğlu, N., Polat, G., Çilekar, Ş., Batum, Ö., & Gülen, Ş. T. (2026). Patient-reported adverse events and management of antifibrotic therapy in IPF: A multicenter, cross-sectional real-world study. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261475558

Vancouver

Turan O, Uğurlu E, Oral Tapan Ö, Sarıoğlu N, Polat G, Çilekar Ş, et al. Patient-reported adverse events and management of antifibrotic therapy in IPF: A multicenter, cross-sectional real-world study. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261475558

BibTeX
@article{Turan2026,
  author = {Turan, Onur and Uğurlu, Erhan and Oral Tapan, Özge and Sarıoğlu, Nurhan and Polat, Gülru and Çilekar, Şule and Batum, Özgür and Gülen, Şule Taş},
  title = {Patient-reported adverse events and management of antifibrotic therapy in IPF: A multicenter, cross-sectional real-world study},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  volume = {20},
  doi = {10.1177/17534666261475558}
}
Kostenlos starten →